{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:51:37Z","timestamp":1793742697850,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T00:00:00Z","timestamp":1717286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T00:00:00Z","timestamp":1717286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Daiichi Sankyo, Inc. and AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We report updated efficacy and safety analyses, including secondary and exploratory efficacy endpoints (median follow-up, 41 months) of DESTINY-Breast03. Patients with advanced HER2-positive metastatic breast cancer previously treated with taxane and trastuzumab were randomized to T-DXd (5.4\u2009mg per kg (261 patients)) or T-DM1 (3.6\u2009mg per kg (263 patients)). The primary endpoint was progression-free survival (PFS) by blinded independent central review and was previously reported. The key secondary endpoint was overall survival (OS). Other secondary endpoints included objective response rate, duration of response and PFS (all by investigator assessment) and safety. At data cutoff, 20 November 2023, median PFS by investigator assessment was 29.0 versus 7.2 months (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.24\u20130.38), the 36-month PFS rate was 45.7% versus 12.4% and median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56\u20130.94) with T-DXd versus T-DM1, respectively. Treatment-emergent adverse events were consistent with the previous analyses. No new instances of grade \u22653 interstitial lung disease or pneumonitis occurred (all grade rate, 16.7% (T-DXd) versus 3.4% (T-DM1)). With longer follow-up, T-DXd continued to demonstrate superior efficacy over T-DM1 with a manageable safety profile. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03529110\">NCT03529110<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-024-03021-7","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T11:02:58Z","timestamp":1717326178000},"page":"2208-2215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"Javier","family":"Cort\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Hurvitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-3166","authenticated-orcid":false,"given":"Joanne W. Y.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Pedrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-7611","authenticated-orcid":false,"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":false,"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6137-9171","authenticated-orcid":false,"given":"Sherene","family":"Loi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano S.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-9484","authenticated-orcid":false,"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Ashfaque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengkang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1896-9015","authenticated-orcid":false,"given":"Anton","family":"Egorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-0336","authenticated-orcid":false,"given":"Erika","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,2]]},"reference":[{"key":"3021_CR1","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal, N. & Iqbal, N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol. Biol. Int. 2014, 852748 (2014).","journal-title":"Mol. Biol. Int."},{"key":"3021_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","volume":"135","author":"C Gutierrez","year":"2011","unstructured":"Gutierrez, C. & Schiff, R. HER2: biology, detection, and clinical implications. Arch. Pathol. Lab. Med. 135, 55\u201362 (2011).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"3021_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon, D. J. et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707\u2013712 (1989).","journal-title":"Science"},{"key":"3021_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"3021_CR5","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: Female Breast Cancer Subtypes seer.cancer.gov\/statfacts\/html\/breast-subtypes.html (2017)."},{"key":"3021_CR6","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997\u20134013 (2013).","journal-title":"J. Clin. Oncol."},{"key":"3021_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102378","volume":"106","author":"SM Swain","year":"2022","unstructured":"Swain, S. M. et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis\u2014focus on proactive monitoring, diagnosis, and management. Cancer Treat. Rev. 106, 102378 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"3021_CR8","unstructured":"American Cancer Society. Breast Cancer HER2 Status www.cancer.org\/cancer\/types\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-her2-status.html (2022)."},{"key":"3021_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21, 519\u2013530 (2020).","journal-title":"Lancet Oncol."},{"key":"3021_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100114","volume":"6","author":"T Grinda","year":"2021","unstructured":"Grinda, T. et al. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008\u20132017 ESME cohort. ESMO Open 6, 100114 (2021).","journal-title":"ESMO Open"},{"key":"3021_CR11","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann. Oncol. 32, 1475\u20131495 (2021).","journal-title":"Ann. Oncol."},{"key":"3021_CR12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792 (2001).","journal-title":"N. Engl. J. Med."},{"key":"3021_CR13","unstructured":"Daiichi Sankyo Co. Ltd. ENHERTU\u00ae Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen daiichisankyo.us\/press-releases\/-\/article\/enhertu-approved-in-the-u-s-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen (2022)."},{"key":"3021_CR14","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.22.00519","volume":"40","author":"SH Giordano","year":"2022","unstructured":"Giordano, S. H. et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J. Clin. Oncol. 40, 2612\u20132635 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3021_CR15","doi-asserted-by":"publisher","first-page":"101541","DOI":"10.1016\/j.esmoop.2023.101541","volume":"8","author":"SA Im","year":"2023","unstructured":"Im, S. A. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open 8, 101541 (2023).","journal-title":"ESMO Open"},{"key":"3021_CR16","unstructured":"Daiichi Sankyo Europe GmbH. Summary of Product Characteristics https:\/\/www.medicines.org.uk\/emc\/product\/12135\/smpc (2024)."},{"key":"3021_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok, M., Joensuu, H. & Isola, J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16, 209 (2014).","journal-title":"Breast Cancer Res."},{"key":"3021_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/CCO.0000000000000656","volume":"32","author":"E Nicol\u00f2","year":"2020","unstructured":"Nicol\u00f2, E., Zagami, P. & Curigliano, G. Antibody\u2013drug conjugates in breast cancer: the chemotherapy of the future? Curr. Opin. Oncol. 32, 494\u2013502 (2020).","journal-title":"Curr. Opin. Oncol."},{"key":"3021_CR19","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097\u20135108 (2016).","journal-title":"Clin. Cancer Res."},{"key":"3021_CR20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y., Hagihara, K., Oitate, M., Naito, H. & Agatsuma, T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107, 1039\u20131046 (2016).","journal-title":"Cancer Sci."},{"key":"3021_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada, T., Sugihara, K., Jikoh, T., Abe, Y. & Agatsuma, T. The latest research and development into the antibody\u2013drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem. Pharm. Bull. 67, 173\u2013185 (2019).","journal-title":"Chem. Pharm. Bull."},{"key":"3021_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s, J. et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med. 386, 1143\u20131154 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3021_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz, S. A. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 401, 105\u2013117 (2023).","journal-title":"Lancet"},{"key":"3021_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras, V. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 732\u2013742 (2017).","journal-title":"Lancet Oncol."},{"key":"3021_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3021_CR26","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, F. et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401, 1773\u20131785 (2023).","journal-title":"Lancet"},{"key":"3021_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell, C. A. et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open 7, 100554 (2022).","journal-title":"ESMO Open"},{"key":"3021_CR28","doi-asserted-by":"publisher","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","volume":"147","author":"AC Wolff","year":"2023","unstructured":"Wolff, A.C. et al. Human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 147, 993\u20131000 (2023).","journal-title":"Arch. Pathol. Lab. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03021-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03021-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03021-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:08:24Z","timestamp":1724047704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03021-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,2]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3021"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03021-7","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,2]]},"assertion":[{"value":"29 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, in the last paragraph of the \u201cSafety\u201d section, the text now reading \u201c\u2026there were two events of left ventricular dysfunction or LVEF decrease\u201d originally read \u201c\u2026there were two events of left ventricular dysfunction or LVEF decrease in each treatment group\u201d and has now been amended for clarity.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: J.C. has received research grants from Roche, ARIAD Pharmaceuticals, AstraZeneca, Baxalta\/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, IQVIA and the Queen Mary University of London; has received honoraria from Roche, Novartis, Eisai, Pfizer, Lilly, Merck Sharp & Dohme, Daiichi Sankyo, AstraZeneca, Gilead and Stemline Therapeutics; has received stock from Leuko (relative) and MAJ3 Capital; has received support for attending meetings, accommodations and\/or travel from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, AstraZeneca, Gilead, Merck Sharp & Dohme and Stemline Therapeutics; has held consulting or advisory roles for Roche, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Lilly, Merck Sharp & Dohme, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, HiberCell, BioInvent, GEMoaB, Gilead, Menarini, Zymeworks, Reveal Genomics, Scorpion Therapeutics, ExpreS2ion Biotechnologies, Jazz Pharmaceuticals, AbbVie, BridgeBio, BioNTech and Biocon; and has the following patents: pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent (J. Cort\u00e9s Cast\u00e1n, A. Piris Gim\u00e9nez, V. Serra Elizalde; WO 2014\/199294A (issued)) and HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy (A. Prat, A. Llombart, J.C.; US 2019\/0338368 A1 (licensed)). S.A.H. has received research grants from Genentech\/Roche, Novartis, GlaxoSmithKline, Sanofi, Pfizer, Amgen, OBI Pharma, Puma Biotechnology, Dignitana, Bayer, BioMarin, Lilly, Merrimack, Cascadian Therapeutics, Seagen, Daiichi Sankyo, MacroGenics, Ambryx, Immunomedics, Pieris Pharmaceuticals, Radius Health, Arvinas, Zymeworks, Gilead Sciences, Phoenix Molecular Designs, CytomX Therapeutics, Samumed, Dantari, Orinove, Greenwich LifeSciences, AstraZeneca\/Daiichi Sankyo, G1 Therapeutics and Orum Therapeutics; has received stock and other ownership interests from ROM Tech; and has received support for attending meetings and\/or travel from Lilly. S.-A.I. has received research grants from AstraZeneca, Pfizer, Roche\/Genentech, Daewoong Pharmaceutical, Eisai and Boryung Pharmaceuticals; and has held consulting or advisory roles at AstraZeneca, Novartis, Roche\/Genentech, Eisai, Pfizer, Amgen, Hanmi, Lilly, MSD and Daiichi Sankyo. H.I. has received research grants from MSD, AstraZeneca, Kyowa Kirin, Daiichi Sankyo, Chugai Pharma, Nihokayaku, Lilly Japan, Novartis, Bayer, Pfizer, Boehringer Ingelheim, Sanofi and Amgen; has received honoraria from Chugai Pharma, AstraZeneca, Eisai, Pfizer, Daiichi Sankyo, Lilly Japan, Kyowa Kirin, Taiho Pharmaceutical and MSD; and has held consulting or advisory roles at Chugai Pharma, Daiichi Sankyo, Pfizer, AstraZeneca, Lilly Japan, Kyowa Kirin, Novartis, MSD and Sanofi. G.C. has received research grants from Merck; has received honoraria from Ellipses Pharma; has received support for attending meetings and\/or travel from Roche\/Genentech, Pfizer, Daiichi Sankyo and AstraZeneca; has a leadership role for the ESMO, the European Society of Breast Cancer Specialists and ESMO Open; is a speakers\u2019 bureau member for Roche\/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, AstraZeneca and Exact Sciences; and has held consulting or advisory roles for Roche\/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol Myers Squibb, Samsung, AstraZeneca, Daiichi Sankyo, Boehringer Ingelheim, GlaxoSmithKline, Seagen, Guardant Health, Veracyte, Celcuity, Hengrui Therapeutics, Menarini, Merck, Exact Sciences, Blueprint Medicines and Gilead Sciences. S.-B.K. has received research grants from Genzyme; has received honoraria from DAEHWA Pharmaceutical, LegoChem Biosciences and Kalbe Farma; has received stock and other ownership interests from Genopeaks; and has held consulting or advisory roles for Lilly, AstraZeneca, DAEHWA Pharmaceutical, ISU Abxis, BeiGene, Daiichi Sankyo\/AstraZeneca, OBI Pharma and Ensol Biosciences. J.W.Y.C. has a leadership role for Precision Oncology; and has held consulting or advisory roles at Lilly. K.Y. has received research grants from Ono Pharmaceutical, MSD, Daiichi Sankyo\/AstraZeneca, AstraZeneca\/MedImmune, Taiho Pharmaceutical, Pfizer, Novartis, Takeda, Sanofi, Seagen, Eisai, Lilly, Genmab, Boehringer Ingelheim, Kyowa Kirin, Haihe Pharmaceutical and Nihokayaku; has received honoraria from Eisai, Pfizer, AstraZeneca, Novartis, Taiho Pharmaceutical, Lilly Japan, Daiichi Sankyo\/AstraZeneca, Takeda, Fujifilm, Ono Pharmaceutical, Chugai Pharma and MSD Oncology; and has held consulting or advisory roles for Chugai Pharma, Ono Pharmaceutical, Novartis, Eisai, OncXerna Therapeutics and Henlius. G.B. has received research grants from Gilead Sciences; has received honoraria from Roche, Eisai, MSD, Lilly, Pfizer, Novartis, Exact Sciences, AstraZeneca\/Daiichi Sankyo, Gilead Sciences and Seagen; has received support for attending meetings and\/or travel from Novartis, Roche, Pfizer, AstraZeneca\/Daiichi Sankyo and Gilead Sciences; and has held consulting or advisory roles for Roche, AstraZeneca\/Daiichi Sankyo, Pfizer, Lilly, Novartis, Gilead Sciences, Exact Sciences, Eisai, MSD, Seagen and Agendia. S.L. has received research grants from Roche\/Genentech, Novartis, Merck, Puma Technology, Bristol Myers Squibb, Seagen, AstraZeneca, Nektar and Lilly; has received honoraria from Roche\/Genentech, Novartis, MSD Oncology and Mersana; has a leadership role for Bristol Myers Squibb; has received support for attending meetings and\/or travel from Bristol Myers Squibb; and has held consulting or advisory roles for Roche\/Genentech, Novartis, G1 Therapeutics, Puma Biotechnology, GlaxoSmithKline, AstraZeneca, Seagen, Bristol Myers Squibb, Silverback Therapeutics, Pfizer, Gilead Sciences, Daiichi Sankyo\/Lilly and Tallac Therapeutics. T.B. has received research grants from Novartis, AstraZeneca, Seagen, Pfizer and Daiichi Sankyo\/AstraZeneca; has received support for attending meetings and\/or travel from Roche, Pfizer, AstraZeneca and Novartis; and has held consulting or advisory roles for Novartis, Pfizer, Seagen, Daiichi Sankyo\/AstraZeneca and Lilly. S.N. is employed by Daiichi Sankyo\/Arqule; and has received stock and other ownership interests from Daiichi Sankyo. S.A. is employed by Daiichi Sankyo. Z.L. is employed by Daiichi Sankyo. A.E. is employed by Daiichi Sankyo\/AstraZeneca; and has received stock and other ownership interests from Daiichi Sankyo\/AstraZeneca. E.H. has received research grants from AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stemcentrx, Genentech\/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Mersana, Millennium, TapImmune, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, MacroGenics, AbbVie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, NuCana, Regeneron, Leap Therapeutics, Taiho Pharmaceutical, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Sutro Biopharma, Zenith Epigenetics, Arvinas, Harpoon, Black Diamond Pharmaceuticals, Orinove, Molecular Templates, Seagen, Compugen, G1 Therapeutics, Karyopharm Therapeutics, the Dana Farber Cancer Hospital, Onconova Therapeutics, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, ImmunoGen, Plexxikon, Amgen, Akeso Biopharma, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repertoire Immune Medicines, Treadwell Therapeutics, Jacobio, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, ProfoundBio, Cullinan Oncology, Bristol Myers Squibb, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics and Stemline Therapeutics; and has held consulting or advisory roles for Pfizer, Genentech\/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Greenwich LifeSciences, Orum Therapeutics, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnology, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services and Zentalis. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}